CP 47,497

CP 47,497
IUPAC ime
	2-[(1R,3S)-3-hidroksicikloheksil]- 5-(2-metiloktan-2-il)fenol
Pravni status
Pravni status	Ilegalan u Nemačkoj i Francuskoj, Klasa B (UK);
Identifikatori
CAS broj	70434-82-1 ; 70434-92-3 (C8 homolog)
ATC kod	none
PubChem	CID 125835
ChEMBL	CHEMBL163701
Hemijski podaci
Formula	C21H34O2
Molarna masa	318,492 g/mol
	SMILES OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]2CCC[C@@H](O)C2; ;

CP 47,497 ili (C7)-CP 47,497 je agonist kanabinoidnog receptora, koji je razvilo preduzeće Pfizer tokom 1980-tih.^[1] Ovaj materijal ima analgetsko dejstvo i koristi se u naučnim istraživanjima. Ono je potentan CB₁ agonist sa K_d vrednošću od 2,1 nM.^[2]^[3]^[4]

Vidi još уреди

Reference уреди

^ Weissman A, Milne GM, Melvin LS Jr. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. Journal of Pharmacology and Experimental Therapeutics. 1982 Nov;223(2):516-23. PMID 6290642
^ Shim JY, Welsh WJ, Howlett AC. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers. 2003;71(2):169-89. PMID 12767117
^ Roger Pertwee. Cannabinoids. Handbook of Experimental Pharmacology Volume 168. Springer. ISBN 978-3-540-22565-2.
^ Little PJ, et al. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. Journal of Pharmacology and Experimental Therapeutics 1988; 247:1046–1051.

Spoljašnje veze уреди

[1] Weissman A, Milne GM, Melvin LS Jr. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. Journal of Pharmacology and Experimental Therapeutics. 1982 Nov;223(2):516-23. PMID 6290642

[2] Shim JY, Welsh WJ, Howlett AC. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers. 2003;71(2):169-89. PMID 12767117

[3] Roger Pertwee. Cannabinoids. Handbook of Experimental Pharmacology Volume 168. Springer. ISBN 978-3-540-22565-2.

[4] Little PJ, et al. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. Journal of Pharmacology and Experimental Therapeutics 1988; 247:1046–1051.

[1]

[2]

[3]

[4]